<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5633</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Colomb. Cardiol.]]></abbrev-journal-title>
<issn>0120-5633</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Cardiologia. Oficina de Publicaciones]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-56332019000200063</article-id>
<article-id pub-id-type="doi">10.1016/j.rccar.2018.05.011</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Analysis of secondary prevention measures implemented in patients with a history of acute coronary syndrome]]></article-title>
<article-title xml:lang="es"><![CDATA[Análisis de las medidas de prevención secundaria introducidas en pacientes con historia de síndrome coronario agudo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[Jorge Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[Manuel Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina-Morales]]></surname>
<given-names><![CDATA[Diego Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Giraldo-Giraldo]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Tecnológica de Pereira-Audifarma S.A Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia ]]></institution>
<addr-line><![CDATA[Pereira ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria Autónoma de las Américas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>26</volume>
<numero>2</numero>
<fpage>63</fpage>
<lpage>69</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-56332019000200063&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-56332019000200063&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-56332019000200063&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To determine the pharmacological measures implemented for secondary prevention in patients with acute coronary syndrome in order to identify whether the implemented management corresponds to recommended clinical practice guidelines and to intervene in those cases where incomplete treatments are found.  Methods:  A pre- and post-quasi-experimental study was performed in patients with acute coronary syndrome who were affiliated with the Colombian health system. The patients were monitored for one year from the occurrence of acute coronary syndrome, and all dispensed medications were reviewed. For those patients in whom a lack of a prescription ((-blockers + renin-angiotensin-aldosterone system inhibitors (RAASi) + dual antiaggregation + statin) was identified, an intervention was performed with their treating physicians, showing the analysis of each case, the missing medication, and the evidence supporting the recommendation. The results were measured three months later.  Results:  A total of 829 patients with acute coronary syndrome who underwent percutaneous coronary intervention (90.1%) or coronary bypass (9.9%) were identified. The mean age was 63.8 ± 10.6 years and 73.1% were men. The recommended pharmacological therapy was completed in 729 patients (87.9% of cases). The intervention performed on the remaining 100 patients was able to add the missing drug in 23.0% of the cases. Statistical analysis showed no significant differences with the drug that should have been initiated nor with the success of the intervention.  Conclusion:  The majority of patients with acute coronary syndrome are adequately treated after percutaneous intervention with medications recommended by the guidelines. Limited success in the adjustment of the management acute coronary syndrome was achieved following the recommendations given to the responsible physicians.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Determinar las medidas de prevención secundaria implementadas en pacientes que sufrieron un síndrome coronario agudo para identificar si corresponden con guías de práctica clínica e intervenir casos con tratamientos incompletos.  Métodos:  Estudio cuasiexperimental, antes y después, en todos los niveles de atención, en el que se incluyeron pacientes que sufrieron un síndrome coronario agudo, afiliados al sistema de salud de Colombia. Se hizo seguimiento un año (1 enero y 31 diciembre de 2014) a partir del episodio del síndrome coronario agudo y se revisó toda la medicación dispensada. En quienes se identificó falta de prescripción ((-bloqueadores + ISRAA + antiagregación dual + estatina) se realizó una intervención sobre sus médicos tratantes mostrando el análisis de cada caso, el medicamento faltante y la evidencia que avala la recomendación. Tres meses después se midieron los resultados.  Resultados:  Se hallaron 829 pacientes con síndrome coronario agudo sometidos a intervención coronaria percutánea (90,1%) o baipás coronario (9,9%). La media de edad fue 63,8 ± 10,6 años y 73,1% fueron hombres. La terapia farmacológica recomendada se cumplió en 729 pacientes (87,9% de casos). La intervención hecha sobre los 100 pacientes restantes logró que agregaran el fármaco faltante en 23,0% de casos. El análisis estadístico no mostró diferencias significativas con el fármaco que debía iniciarse ni con el éxito de la intervención.  Conclusión:  La mayoría de pacientes que sufrieron un síndrome coronario agudo están tratados de manera adecuada después de la intervención percutánea, con medicamentos recomendados por las guías. Se logró un limitado éxito en el ajuste del manejo tras las recomendaciones dadas a los médicos responsables.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Acute coronary syndrome]]></kwd>
<kwd lng="en"><![CDATA[Primary prevention]]></kwd>
<kwd lng="en"><![CDATA[Optimal medical treatment]]></kwd>
<kwd lng="en"><![CDATA[Guideline]]></kwd>
<kwd lng="en"><![CDATA[Pharmacology]]></kwd>
<kwd lng="es"><![CDATA[Síndrome coronario agudo]]></kwd>
<kwd lng="es"><![CDATA[Prevención primaria]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento médico óptimo]]></kwd>
<kwd lng="es"><![CDATA[Guía terapéutica]]></kwd>
<kwd lng="es"><![CDATA[Farmacología]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1997</year>
<volume>349</volume>
<page-range>1498-504</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nabel]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A tale of coronary artery disease and myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>366</volume>
<page-range>54-63</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Sidney]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chandra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sorel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Selby]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population trends in the incidence and outcomes of acute myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>2155-65</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Guía de práctica clínica para el Síndrome Coronario Agudo. Sistema General de Seguridad Social en Salud.]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Bogotá, Colombia ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith Jr]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bonow]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[Braun]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Creager]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Franklin]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2011</year>
<volume>58</volume>
<page-range>2432-46</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Atar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Badano]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Blomstrom-Lundqvist]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Borger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Task Force on the management of STsegment elevation acute myocardial infarction of the European Society of Cardiology (ESC), ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2012</year>
<volume>33</volume>
<page-range>2569-619</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montalescot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wiviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Gibson]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[McCabe]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38) double-blind, randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2009</year>
<volume>373</volume>
<page-range>723-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Steinberg]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Mega]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2006</year>
<volume>48</volume>
<page-range>438-45</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[McCabe]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Rader]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rouleau]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Belder]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>350</volume>
<page-range>1495-504</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>ACE Inhibitor Myocardial Infarction Collaborative Group</collab>
<article-title xml:lang=""><![CDATA[Indications for ACE inhibitors in the early treatment of acute myocardial infarction systematic overview of individual data from 100,000 patients in randomized trials.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1998</year>
<volume>97</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2202-12</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moyé]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Basta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brown Jr]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cuddy]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction Results of the survival and ventricular enlargement trial. The SAVE Investigators]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1992</year>
<volume>327</volume>
<page-range>669-77</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2002</year>
<volume>324</volume>
<page-range>71-86</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freemantle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[beta Blockade after myocardial infarction: systematic review and meta regression analysis]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1999</year>
<volume>318</volume>
<page-range>1730-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[LX]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Peto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction randomized placebo-controlled trial]]></article-title>
<collab>COMMIT collaborative group</collab>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<page-range>1607-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ball]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACE inhibition, atherosclerosis and myocardial infarction-the AIRE Study in practice Acute Infarction Ramipril Efficacy Study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>1994</year>
<volume>15</volume>
<numero>^sB</numero>
<issue>^sB</issue>
<supplement>B</supplement>
<page-range>20-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallagher]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Byrne]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kennedy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[O'Mahony]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment) Consensus validation]]></article-title>
<source><![CDATA[Int J Clin Pharmacol Ther]]></source>
<year>2008</year>
<volume>46</volume>
<page-range>72-83</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamood]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hamood]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Almog]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants of adherence to evidence-based;1; therapy after acute myocardial infarction]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>975-85</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[van der Wulp]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Appelman]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bruijne]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adherence to guidelines for the prescription of secondary prevention medication at hospital discharge after acute coronary syndrome a multicentre study]]></article-title>
<source><![CDATA[Neth Heart J]]></source>
<year>2015</year>
<volume>23</volume>
<page-range>214-21</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamood]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hamood]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Almog]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of adherence to evidence-based therapy after acute myocardial infarction on all-cause mortality]]></article-title>
<source><![CDATA[Pharmacoepidemiol Drug Saf]]></source>
<year>2015</year>
<volume>24</volume>
<page-range>1093-104</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iviott]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Braunwald]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[McCabe]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Montalescot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ruzyllo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Gottlieb]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>357</volume>
<page-range>2001-15</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Tanguay]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Jolly]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Joyner]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CURRENT-OASIS 7 trial investigators Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomized factorial trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<page-range>1233-43</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Bassand]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Chrolavicius]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose comparisons of clopidogrel and aspirin in acute coronary syndromes]]></article-title>
<collab>CURRENT-OASIS 7 Investigators</collab>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>363</volume>
<page-range>930-42</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Gibson]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Sendon]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Montalescot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Theroux]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>352</volume>
<page-range>1179-89</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dézsi]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differences in the clinical effects of angiotensinconverting enzyme inhibitors and Angiotensin receptor blockers a critical review of the evidence]]></article-title>
<source><![CDATA[Am J Cardiovasc Drugs]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>167-73</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rosano]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Not just numbers, but years of science putting the ACE inhibitor-ARB meta-analyses into context]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>2013</year>
<volume>166</volume>
<page-range>286-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Velazquez]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rouleau]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Kober]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Maggioni]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<page-range>1893-906</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pfeffer]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Greaves]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Glynn]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[LaMotte]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction The heal ing and early afterload reducing therapy trial]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1997</year>
<volume>95</volume>
<page-range>2643-51</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kober]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Torp-Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsen]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bagger]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Eliasen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lyngborg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction Trandolapril Cardiac Evaluation (TRACE) Study Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1995</year>
<volume>333</volume>
<page-range>1670-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Londoño-Builes]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Echeverri-Cataño]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Orozco]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2016</year>
<volume>36</volume>
<page-range>59-66</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Giraldo-Giraldo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of conventional release verapamil prescription in patients with arterial hypertension]]></article-title>
<source><![CDATA[Rev Calid Asist]]></source>
<year>2015</year>
<volume>30</volume>
<page-range>72-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Portilla]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Duque]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Machado-Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intervention in the prescribing of the combination of an angiotensin converting enzyme inhibitor and an angiotensin-ii receptor blocker]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2016</year>
<volume>48</volume>
<page-range>272-4</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anglemyer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Horvath]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Bero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2014</year>
<page-range>MR000034</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
